for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regeneron Pharmaceuticals Inc

REGN.O

Latest Trade

620.21USD

Change

0.00(0.00%)

Volume

19

Today's Range

--

 - 

--

52 Week Range

271.37

 - 

664.64

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
620.21
Open
0.00
Volume
19
3M AVG Volume
26.11
Today's High
--
Today's Low
--
52 Week High
664.64
52 Week Low
271.37
Shares Out (MIL)
106.39
Market Cap (MIL)
65,985.63
Forward P/E
22.80
Dividend (Yield %)
--

Next Event

Q3 2020 Regeneron Pharmaceuticals Inc Earnings Release

Latest Developments

More

Regeneron Announces Pricing Of Public Offering Of Senior Unsecured Notes

Adicet Bio Receives $10 Million Milestone Payment From Regeneron

Regeneron Pharmaceuticals Q2 GAAP Earnings Per Share $7.61

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Industry

Biotechnology & Drugs

Contact Info

777 Old Saw Mill River Rd

TARRYTOWN, NY

10591-6717

United States

+1.914.8477000

https://www.regeneron.com/

Executive Leadership

P. Roy Vagelos

Chairman of the Board, Director

Leonard S. Schleifer

President, Chief Executive Officer, Director

George D. Yancopoulos

President, Chief Scientific Officer, Director

Robert E. Landry

Chief Financial Officer, Executive Vice President - Finance

Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

Key Stats

2.11 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

5.9K

2018

6.7K

2019

7.9K

2020(E)

8.1K
EPS (USD)

2017

16.320

2018

22.840

2019

24.670

2020(E)

28.129
Price To Earnings (TTM)
24.01
Price To Sales (TTM)
8.25
Price To Book (MRQ)
7.26
Price To Cash Flow (TTM)
20.58
Total Debt To Equity (MRQ)
24.47
LT Debt To Equity (MRQ)
7.90
Return on Investment (TTM)
26.89
Return on Equity (TTM)
21.62

Latest News

Latest News

Regeneron profit beats, expects early results from COVID-19 trials in September

Regeneron Pharmaceuticals Inc <REGN.O> beat second-quarter profit estimates on Wednesday, helped by higher sales of its eczema drug Dupixent and said it expects initial data from ongoing trials of its COVID-19 antibody cocktail next month.

Regeneron Pharma posts quarterly profit on $228 mln gain

Regeneron Pharmaceuticals Inc reported a quarterly profit on Wednesday that rose more than four times, helped by a $228 million gain and on higher sales of its blockbuster eczema treatment Dupixent.

Regeneron says antibody cocktail prevents and treats COVID-19 in animals

Regeneron Pharmaceuticals Inc said on Monday that the COVID-19 antibody drug combination it is developing both prevented and treated the disease in rhesus macaques and hamsters, adding to hope that it might work for people.

U.S. signs $450 million contract with Regeneron for COVID-19 therapy

The U.S. government signed a $450 million contract with Regeneron Pharmaceuticals Inc <REGN.O> for its potential COVID-19 antibody cocktail, the drugmaker said on Tuesday.

BRIEF-Regeneron Announces Manufacturing And Supply Agreement For BARDA And U.S. Department Of Defense For REGN-COV2 Anti-Viral Antibody Cocktail

* REGENERON ANNOUNCES MANUFACTURING AND SUPPLY AGREEMENT FOR BARDA AND U.S. DEPARTMENT OF DEFENSE FOR REGN-COV2 ANTI-VIRAL ANTIBODY COCKTAIL

Regeneron signs $450 mln contract with U.S. govt for COVID-19 therapy

Regeneron Pharmaceuticals Inc said on Tuesday the U.S. government has granted the drugmaker a $450 million contract to make and supply its double antibody cocktail that is being tested against COVID-19.

Regeneron starts COVID-19 antibody cocktail late-stage trials, shares rise

Regeneron Pharmaceuticals Inc <REGN.O> said on Monday it has started late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating COVID-19.

Regeneron begins COVID-19 antibody cocktail late-stage trial

Regeneron Pharmaceuticals Inc said on Monday it began late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating COVID-19.

BRIEF-Regeneron Announces Start Of Regn-Cov2 Phase 3 Covid-19 Prevention Trial With National Institute Of Allergy And Infectious Diseases

* REGENERON ANNOUNCES START OF REGN-COV2 PHASE 3 COVID-19 PREVENTION TRIAL IN COLLABORATION WITH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID)

Regeneron, Sanofi arthritis drug fails COVID-19 study

Regeneron Pharmaceuticals Inc and Sanofi said on Thursday their rheumatoid arthritis drug Kevzara failed to meet the main goals of a U.S. study testing it in the most critically ill COVID-19 patients.

Regeneron, Sanofi arthritis drug fails late-stage study in COVID-19 patients

Regeneron Pharmaceuticals Inc and Sanofi said on Thursday their rheumatoid arthritis drug Kevzara failed to meet the main goals of a late-stage study testing it in COVID-19 patients.

BRIEF-Regeneron Says Co And Sanofi Provide Update On Kevzara Phase 3 U.S. Trial In COVID-19 Patients

* REGENERON AND SANOFI PROVIDE UPDATE ON KEVZARA® (SARILUMAB) PHASE 3 U.S. TRIAL IN COVID-19 PATIENTS

BRIEF-Regeneron Pharmaceuticals Inc Says "There Is No Merit To Civil Complaint Filed By U.S. Attorney For District Of Massachusetts"

* REGENERON PHARMACEUTICALS INC SAYS "THERE IS NO MERIT TO CIVIL COMPLAINT FILED BY U.S. ATTORNEY FOR DISTRICT OF MASSACHUSETTS"

U.S. claims Regeneron paid kickbacks via charity to boost expensive drug

The U.S. Justice Department on Wednesday sued Regeneron Pharmaceuticals Inc, accusing it of using a charity that helps cover Medicare patients' drug costs as a means to pay kickbacks for using its expensive macular degeneration drug Eylea.

U.S. alleges Regeneron used drug charity to pay kickbacks

The U.S. Justice Department on Wednesday sued Regeneron Pharmaceuticals Inc, accusing it of using a charity that helps cover Medicare patients' drug costs as a means to pay kickbacks for using its expensive macular degeneration drug Eylea.

BRIEF-Kymab Wins Supreme Court Case Against Regeneron

* KYMAB WINS SUPREME COURT CASE AGAINST REGENERON Source text for Eikon: Further company coverage:

BRIEF-Regeneron's Dupixent Included In List Of Overseas Approved Drugs That Meet Urgent Clinical in China

* DUPIXENT® (DUPILUMAB) APPROVED IN CHINA FOR ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Regeneron begins human testing of COVID-19 antibody cocktail

Regeneron Pharmaceuticals Inc on Thursday said it has begun human testing of its experimental antibody cocktail as a treatment for COVID-19, the disease caused by the novel coronavirus.

Regeneron begins human testing of COVID-19 antibody cocktail

Regeneron Pharmaceuticals Inc on Thursday said it has begun human testing of its experimental antibody cocktail as a treatment for COVID-19, the disease caused by the novel coronavirus.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up